Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ledipasvir + sofosbuvir
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Harvoni is a fixed-dose combination drug containing ledipasvir and sofosbuvir, developed by Gilead Sciences for the treatment of chronic hepatitis C virus (HCV) infection. Ledipasvir is an inhibitor of the HCV NS5A protein, which is essential for viral replication and assembly. Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-dependent RNA polymerase, acting as a chain terminator during viral RNA synthesis. This combination is highly effective across multiple HCV genotypes (1, 4, 5, and 6). In the context of Tanta University, it has been evaluated in Phase 4 clinical trials for efficacy in pediatric patients with beta-thalassemia and HCV infection, specifically monitoring liver fibrosis markers like hyaluronic acid.
- Brand names
- HarvoniMyHep LVIR
- Other names
- Ledipasvir 90 MG / Sofosbuvir 400 MGLedipasvir/Sofosbuvir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on ledipasvir + sofosbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ledipasvir + sofosbuvir.